載入...
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
INTRODUCTION: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and their associated costs and effects in daily clinical practice. We estimated the real-wor...
Na minha lista:
| 發表在: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5439671/ https://ncbi.nlm.nih.gov/pubmed/28531203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177364 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|